Advocacy intelligence hub — real-time data for patient organizations
Novartis Pharmaceuticals — PHASE1
PROCYSBI: FDA approved
PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Cystagon: FDA approved
Treatment of nephropathic cystinosis in adults and children.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Cystagon
Recordati
Patient Assistance Programs1
PROCYSBI
Horizon Therapeutics USA, Inc.
PROCYSBI
(cysteamine enteric coated)Orphan drugHorizon Therapeutics USA, Inc.
12.1 Mechanism of Action Cysteamine is an aminothiol that participates within lysosomes in a thiol-disulfide interchange reaction converting cystine i...